The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

被引:0
作者
Merlin C. Thomas
David Z. I. Cherney
机构
[1] Monash University,Department of Diabetes, Central Clinical School
[2] University of Toronto,Department of Medicine, Division of Nephrology, Toronto General Hospital
来源
Diabetologia | 2018年 / 61卷
关键词
Diabetes; Glucose-lowering; Review; SGLT2; SGLT2 inhibitor; Sodium–glucose cotransporter 2; Type 2 diabetes;
D O I
暂无
中图分类号
学科分类号
摘要
Inhibition of the sodium–glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney has a broad range of effects on renal function and plasma volume homeostasis, as well as on adiposity and energy metabolism across the entire body. SGLT2 inhibitors are chiefly used in type 2 diabetes for glucose control, achieving reductions in HbA1c of 7–10 mmol/mol (0.6–0.9%) when compared with placebo. This glucose-lowering activity is proportional to the ambient glucose concentration and glomerular filtration of this glucose, so may be greater in those with poor glycaemic control and/or hyperfiltration at baseline. Equally, the glucose-lowering effects of SGLT2 inhibitors are attenuated in individuals without diabetes and those with a reduced eGFR. However, unlike the glucose-lowering effects of SGLT2 inhibitors, the spill-over of sodium and glucose beyond the proximal nephron following SGLT2 inhibition triggers dynamic and reversible realignment of energy metabolism, renal filtration and plasma volume without relying on losses into the urine. In addition, these processes are observed in the absence of significant glucosuria or ongoing natriuresis. In the long term, the resetting of energy/salt/water physiology following SGLT2 inhibition has an impact, not only on adiposity, renal function and blood pressure control, but also on the health and survival of patients with type 2 diabetes. A better understanding of the precise biology underlying the acute actions of SGLT2 inhibitors in the kidney and how they are communicated to the rest of the body will likely lead to improved therapeutics that augment similar pathways in individuals with, or even without, diabetes to achieve additional benefits.
引用
收藏
页码:2098 / 2107
页数:9
相关论文
共 197 条
[41]  
Cui W(2017)Empagliflozin and progression of kidney disease in type 2 diabetes Diabetes Care 40 1479-F234
[42]  
Li D(2015)Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis Am J Physiol Ren Physiol 309 F227-776
[43]  
Ferrannini E(2017)Acute SGLT inhibition normalizes O Diabetes Care 40 771-469
[44]  
Del Prato S(2005) tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats Arch Intern Med 165 466-432
[45]  
Nauck M(2009)Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes Curr Opin Nephrol Hypertens 18 428-F83
[46]  
Duran-Garcia S(2015)Anemia with impaired erythropoietin response in diabetic patients Am J Physiol Ren Physiol 308 F77-63
[47]  
Bonner C(2018)Solute carrier family 2, member 9 and uric acid homeostasis Diabetes Metab Syndr 12 59-657
[48]  
Kerr-Conte J(2017)Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus N Engl J Med 377 644-375
[49]  
Gmyr V(2017)SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms J Am Soc Nephrol 28 368-F422
[50]  
Ferrannini E(2018)Canagliflozin and cardiovascular and renal events in type 2 diabetes Am J Physiol Ren Physiol 314 F412-621